[耻骨后前列腺根治性切除术后勃起功能障碍的磷酸二酯酶5抑制剂治疗]

[Treatment of erectile dysfunction after radical retropubic prostatectomy with PDE5 inhibitor].

作者信息

Jin Wei, Huang Yi-rang

机构信息

Department of Urology, Renji Hospital, Shanghai Second Medical University, Shanghai 200001, China.

出版信息

Zhonghua Nan Ke Xue. 2005 Sep;11(9):708-12.

PMID:16209216

Abstract

The rate of erectile dysfunction after radical retropubic prostatectomy is from 10% to 100%. The prevalence of erectile dysfunction after nerve-sparing radical prostatectomy is more than one third. In the patients who had undergone bilateral NS, 72% responded to sildenafil, 71.7% and 59.7% responded to 20 mg and 10 mg of vardenafil respectively. For all randomized patients who received tadalafil, the mean percentage of successful penetration attempts was 54% and the mean percentage of successful intercourse attempts was 41%. For the subgroup with evidence of postoperative tumescence these values were 69% and 52%, respectively. No head-to-head trials have been performed with sildenafil, vardenafil and tadalafil in treatment of erectile dysfunction after radical prostatectomy.

摘要

耻骨后根治性前列腺切除术后勃起功能障碍的发生率为10%至100%。保留神经的根治性前列腺切除术后勃起功能障碍的患病率超过三分之一。在接受双侧保留神经手术的患者中，72%对西地那非有反应，分别有71.7%和59.7%的患者对20毫克和10毫克伐地那非有反应。对于所有接受他达拉非治疗的随机分组患者，成功插入尝试的平均百分比为54%，成功性交尝试的平均百分比为41%。对于有术后阴茎勃起证据的亚组，这些值分别为69%和52%。尚未进行西地那非、伐地那非和他达拉非治疗根治性前列腺切除术后勃起功能障碍的直接对比试验。